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Background: Whether high maintenance-dose clopidogrel of 150mg/d (HMDC) can provide adequate antiplatelet effect in CYP2C19 poor 
metabolizers can be an important issue for personalized antiplatelet therapy. In addition, whether two most common variants (*2 and *3) during 
HMDC therapy show similar loss-of-function (LoF) impact has not been determined.
Methods: PCI-treated patients (n=155) were enrolled. Platelet reactivity was assessed with light transmittance aggregometry (LTA) at predischarge 
and after 1-month HMDC therapy. CYP2C19 genotyping was performed with ABI SNaPshot method.
Results: CYP2C19 LoF alleles were observed in 63.9% of total (n=99) (*1/*2=55; *1/*3=18; *2/*2=17; *2/*3=9). Additive platelet inhibition 
of HMDC vs. standard-dose clopidogrel was significantly decreased in patients with two CYP2C19 LoF alleles (` coefficient, -4.805; 95% CI, -8.962 
to -0.648; p=0.024). The influence of CYP2C19*3 allele on platelet measures during HMDC therapy seems greater compared to CYP2C19*2 allele; 
carriage of CYP2C19*1/*3 genotype showed similar platelet measures compared with CYP2C19*2/*2 genotype (Figure).
Conclusions: HMDC therapy doesn’t enhance platelet inhibition significantly in CYP2C19 poor metabolizers. Carriage effect of CYP2C19*3 allele 
during HMDC therapy appears greater compared with CYP2C19*2 allele, which clinical impact needs to be explored in future clinical trials.
 
